Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152667 | 1.00 | ALDH1A1 (0.44) | ALDH1A1GAAPPARGKDM4EMEN1 | |
| SCHEMBL31015744 | 0.94 | ALDH1A1 (0.41) | ALDH1A1GAAPPARGKDM4EMEN1 | |
| SCHEMBL27307968 | 0.91 | ALDH1A1 (0.44) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL29920916 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL24820732 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL24820699 | 0.83 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL24820315 | 0.81 | ALDH1A1 (0.60) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL27086188 | 0.81 | ALDH1A1 (0.45) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL30792038 | 0.80 | SCN9A (0.35) | PPARGEIF4E | |
| SCHEMBL29189938 | 0.80 | SCN9A (0.35) | PPARGEIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022217276-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | ALDH1A1 4641/4885GAA 792/4885PPARG 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.